Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 03, 2015 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium to Provide Update on CD47 Immune Checkpoint Inhibitor Program at the 2015 American Society of Hematology Annual Meeting

TORONTO, ONTARIO--(Marketwired - Dec. 3, 2015) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR) an immuno-oncology company developing innovative therapies for the treatment of cancer,...
September 30, 2015 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Provides Update on CD47 Program

TORONTO, ONTARIO--(Marketwired - Sept. 30, 2015) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), an immuno-oncology company developing innovative therapies for the treatment of...
May 29, 2015 17:00 ET | Source: Trillium Therapeutics Inc.

Trillium Announces Voting Results From the Annual Meeting of Shareholders

TORONTO, May 29, 2015 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the...
April 16, 2015 08:45 ET | Source: Trillium Therapeutics Inc.

Trillium to Provide Update on CD47 Program at the 2015 American Association for Cancer Research Annual Meeting

TORONTO, April 16, 2015 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today...
April 07, 2015 16:01 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Announces Completion of Public Offering of Securities

TORONTO, April 7, 2015 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced...
April 01, 2015 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Announces Pricing of Public Offering of Securities

TORONTO, April 1, 2015 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced...
March 30, 2015 16:01 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Announces Proposed Public Offering of Securities

TORONTO, March 30, 2015 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced...
March 27, 2015 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Announces Appointment of Eric L. Sievers, M.D. as Chief Medical Officer

TORONTO, March 27, 2015 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium") (Nasdaq:TRIL) (TSX:TR), an immuno-oncology company developing innovative therapies for the treatment of cancer,...
March 25, 2015 14:45 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics to Present at the 5th Annual Cancer Immunotherapy Conference

TORONTO, March 25, 2015 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TR), an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced...
December 18, 2014 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics to List Common Shares on the NASDAQ Capital Market Under the Symbol TRIL

TORONTO, Dec. 18, 2014 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium") (TSX:TR) (OTCQX:SCTPF), an immuno-oncology company developing innovative therapies for the treatment of cancer, today...